Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million for the quarter, compared to the consensus estimate of $4.08 million. During the same period last year, the company posted ($0.15) earnings per share. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

Shares of ZVRA traded up $0.06 during midday trading on Tuesday, hitting $8.61. 426,215 shares of the stock traded hands, compared to its average volume of 536,511. The firm has a market capitalization of $453.06 million, a PE ratio of -5.13 and a beta of 1.93. The business's 50 day moving average price is $7.80 and its two-hundred day moving average price is $6.27. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ZVRA shares. Maxim Group lifted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. JMP Securities assumed coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an "outperform" rating and a $17.00 price objective for the company. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Wednesday, September 18th. Roth Mkm increased their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. Finally, Guggenheim initiated coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $20.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $20.83.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.